Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

"This approval begins a new era of precision medicine for patients in China with advanced prostate cancer who have historically had a poor prognosis and few treatment options."

AstraZeneca and MSD's Lynparza (olaparib) has been granted conditional approval in China to treat adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following treatment that included a new hormonal agent (abiraterone, enzalutamide).

In China, prostate cancer is the sixth most prevalent cancer in men, with approximately 115,000 new patients diagnosed each year and about 7% have germline BRCA mutations.1,2 Prostate cancer patients with these mutations are more likely to have poorer outcomes than those without the mutations.3 Around 70% of prostate cancer patients in China have advanced disease at the time of diagnosis, and for those with mCRPC, the median survival is less than two years.4,5

The approval by China's National Medical Products Administration was based on a subgroup analysis of the PROfound Phase III trial, which showed that Lynparza demonstrated a substantial improvement in radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone or enzalutamide in men with BRCA1/2 mutations. Continued approval is contingent upon verification and description of clinical benefit in a planned bridging trial with Chinese patients.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: "This approval begins a new era of precision medicine for patients in China with advanced prostate cancer who have historically had a poor prognosis and few treatment options. Lynparza more than tripled radiographic progression-free survival in the PROfound trial and is the only PARP inhibitor to show an overall survival benefit compared to treatment with new hormonal agents for men with BRCA-mutated metastatic castration-resistant prostate cancer."

Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories, said: "The approval underscores the critical importance of BRCA testing in men with prostate cancer. We are proud to provide a new personalised treatment option for men with this devastating disease in China, and we will continue to collaborate with the Chinese government and healthcare organisations to bring Lynparza to patients who need it."

The subgroup analysis from the PROfound Phase III trial showed Lynparza reduced the risk of disease progression or death by 78% (based on a hazard ratio [HR] of 0.22, 95% confidence interval [CI] 0.15-0.32; nominal p<0.0001) and improved rPFS to a median of 9.8 months versus 3.0 with abiraterone or enzalutamide in men with mCRPC with BRCA1/2 mutations. In addition, Lynparza reduced the risk of death by 37% (HR of 0.63, 95% CI 0.42-0.95) with median OS of 20.1 months versus 14.4 with abiraterone or enzalutamide.

Tags : #LatestAstrazenecaNewsJune24 #LatestPharmaNewsJune24 #tREATMENTFORCancer

Related Stories

04 Apr

Beyond the Baby Bump: Can Delayed Pregnancy Increase Autism Risk in Children

Rather than discouraging older women from conceiving, the focus should be on education, preparation, and providing comprehensive prenatal care.

View
03 Apr

Is This the Future of Physiotherapy? Inside Stance Health’s $1M Expansion

With the right mix of expertise, funding, and innovation, the company will not just be filling a gap but also build a future where effective MSK care is accessible to all.

View
03 Apr

The Daily Shower Debate: Are You Washing Away Your Skin’s Health?

Adopting a mindful approach, such as choosing gentle skincare products, limiting shower time, and maintaining hydration, can ensure that your hygiene routine works in harmony with your body’s natural needs.

View
02 Apr

World Autism Awareness Day: Breaking the Chains of Stigma in India

Are we ready to create a world that embraces neurodiversity, or will we continue to let ignorance dictate the lives of millions?

View
02 Apr

DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?

As the healthcare landscape evolves, initiatives like these will determine the future of medical care in the country.

View
02 Apr

From Scroll to Squint: How Reels Are Reshaping Your Vision

By adopting healthier screen habits and prioritizing eye care, we can prevent the irreversible damage caused by prolonged digital exposure.

View
02 Apr

The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time Rest

By implementing screen-free bedtime routines, reducing blue light exposure, and prioritizing sleep hygiene, we can reclaim the restful nights we deserve.

View
02 Apr

High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?

It’s time to prioritize human life over convenience and invest in smarter urban designs to empower communities with the knowledge and tools needed to act swiftly in times of crisis.

View
31 Mar

Doomscrolling at Midnight: How Indians Are Sacrificing Sleep for Screens

Public health initiatives should address sleep disorders with the same urgency as other health concerns. By prioritizing sleep, India can take a major step towards improving overall well-being and productivity.

View
31 Mar

Tired of Stomach Cramps? These Simple Foods Can Heal Your Gut

By making mindful food choices, one can significantly reduce symptoms, avoid severe complications, and improve quality of life.

View

-Advertisements-




Trending Now

Beyond the Baby Bump: Can Delayed Pregnancy Increase Autism Risk in ChildrenApril 04, 2025
University of Manchester invites applications for MA Social AnthropologyApril 03, 2025
Ahead of World Health Day, Sova Health Launches Advanced Microbiome Tests & Evidence-Based Precision Supplements April 03, 2025
Half of women cannot make decisions about their reproductive health and bodily autonomyApril 03, 2025
UGRO CAPITAL LIMITED PUBLIC ISSUE OF SECURED, RATED, LISTED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (SECURED NCDS) OPENS TODAY EFFECTIVE ANNUALIZED YIELD UP TO 11.01% PER ANNUM* April 03, 2025
SF Airlines Entrusts Çelebi India with Freighter Handling at Kempegowda International Airport, BengaluruApril 03, 2025
Is This the Future of Physiotherapy? Inside Stance Health’s $1M ExpansionApril 03, 2025
The Daily Shower Debate: Are You Washing Away Your Skin’s Health?April 03, 2025
The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025
Zigly launches 2 pet hospitals, opens 4 new stores; expects ARR to more than double in 1-2 yearsApril 01, 2025